stock.name

Abbott Laboratories

ABT

Market Cap$206.52B
Close$

Compare Abbott Laboratories

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Abbott LaboratoriesAbbott Laboratories36.11.73%15%5.20.4
marketMarket Avg49.61.28%30%6.11.1
HealthcareHealthcare Avg32.71.25%19%7.40.9

Earnings Call Q4 2023

January 24, 2024 - AI Summary

Abbott reported strong fourth quarter results, with organic sales growth of 2.1% and double-digit growth in underlying base business sales.
The company provided a positive outlook for 2024, forecasting organic sales growth of 8% to 10% (excluding COVID testing) and adjusted earnings per share of $4.50 to $4.70.
Abbott's diversified portfolio and strategic investments during the pandemic have positioned the company for sustainable growth beyond the pandemic.
Key growth drivers include the nutrition segment, which is expected to benefit from market leadership and expansion into the adult nutrition segment.
$122.13

Current Fair Value

2.2% upside

Undervalued by 2.2% based on the discounted cash flow analysis.

Share Statistics

Market cap$206.52 Billion
Enterprise Value$213.92 Billion
Dividend Yield$2.0646 (1.73%)
Earnings per Share$3.27
Beta0.51
Outstanding Shares1,735,184,289
Avg 30 Day Volume5,817,376

Return

Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio36.09
PEG66.45
Price to Sales5.19
Price to Book Ratio5.43
Enterprise Value to Revenue5.33
Enterprise Value to EBIT33.02
Enterprise Value to Net Income37
Total Debt to Enterprise0.07
Debt to Equity0.38

Revenue Sources

No data

ESG Score

No data

About Abbott Laboratories

CEO: Robert Ford